索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]耿礼倩,陈治松,宋浩明.心房颤动与炎性因子[J].国际心血管病杂志,2021,06:326-329.
点击复制

心房颤动与炎性因子(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年06期
页码:
326-329
栏目:
综述
出版日期:
2021-12-01

文章信息/Info

Title:
-
作者:
耿礼倩; 陈治松; 宋浩明
200000 上海,同济大学医学院(耿礼倩); 200092 上海,同济大学附属同济医院心血管内科(陈治松,宋浩明)
Author(s):
-
关键词:
心房颤动;  炎性反应;  炎性因子
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.06.002
文献标识码:
-
摘要:
炎性反应与心房的电重构、结构重构密切相关,参与心房颤动(房颤)的发生与维持。炎性因子与心房颤动的发生发展以及心脏手术后复发有关。该文介绍房颤与C反应蛋白、白细胞介素、肿瘤坏死因子-α、单核细胞趋化蛋白-1、生长分化因子-15等的相关性。他汀类、N-3多不饱和脂肪酸结合抗氧化维生素、糖皮质激素等抑炎药物以及低强度的迷走神经抑制可以有效降低患者血清中炎性因子水平,可能用于预防或治疗房颤。
Abstract:
-

参考文献/References

[1] Liu MX, Li W, Wang HB, et al. CTRP9 ameliorates atrial inflammation, fibrosis, and vulnerability to atrial fibrillation in post-myocardial infarction rats[J]. J Am Heart Assoc, 2019, 8(21):e013133.
[2] Liu Z, Finet JE, Wolfram JA, et al. Calcium/calmodulin-dependent protein kinase Ⅱ causes atrial structural remodeling associated with atrial fibrillation and heart failure[J]. Heart Rhythm, 2019, 16(7):1080-1088.
[3] Liao J, Wu QF, Qian C, et al. TRPV4 blockade suppresses atrial fibrillation in sterile pericarditis rats[J]. JCI Insight, 2020, 5(23):e137528.
[4] Zhou HS, Peng DW, Lai YY, et al. Activation of PKCα participates in the reduction of Ikur in atrial myocytes induced by tumour necrosis factor-α[J]. Clin Exp Pharmacol Physiol, 2020, 48(3):435-442.
[5] Lazzerini PE, Laghi-Pasini F, Acampa M, et al. Systemic inflammation rapidly induces reversible atrial electrical remodeling: the role of interleukin-6-mediated changes in connexin expression[J]. J Am Heart Assoc, 2019, 8(16):e011006.
[6] Narducci ML, Pelargonio G, Russo AD, et al. Role of tissue C-reactive protein in atrial cardiomyocytes of patients undergoing catheter ablation of atrial fibrillation: pathogenetic implications[J]. Europace, 2011, 13(8):1133-1140.
[7] Jiang ZQ, Dai LD, Song ZY, et al. Association between C-reactive protein and atrial fibrillation recurrence after catheter ablation: a meta-analysis[J]. Clin Cardiol, 2013, 36(9):548-554.
[8] Amdur R, Mukherjee M, Go A, et al. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC study[J]. PLoS One, 2016, 11(2):e0148189.
[9] 戴艳枝, 王晓华, 刘秋玲, 等. 白细胞介素-1β、白细胞介素-8及肿瘤坏死因子-α与房颤伴凝血功能异常的相关性[J].中国当代医药, 2019, 26(23):4-7.
[10] Matsushita N, Ishida N, Ibi M, et al. IL-1β Plays an important role in pressure overload-induced atrial fibrillation in mice[J]. Biol Pharm Bull, 2019, 42(4):543-546.
[11] Silva R. Influence of inflammation and atherosclerosis in atrial fibrillation[J]. Curr Atheroscler Rep, 2017, 19(1):2.
[12] Luan Y, Guo YY, Li SF, et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease[J]. Europace, 2010, 12(12):1713-1718.
[13] Damås JK, Aukrust P, Ueland T, et al. Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes[J]. Basic Res Cardiol, 2001, 96(4):345-352.
[14] Takahashi N, Kume O, Wakisaka O, et al. Novel strategy to prevent atrial fibrosis and fibrillation[J]. Circ J, 2012, 76(10):2318-2326.
[15] Zhang GG, Zhang L, Zhou XH, et al. Monocyte chemoattractant protein-1-induced protein in age-related atrial fibrillation and its association with circulating fibrosis biomarkers[J]. Cardiology, 2019, 142(4):244-249.
[16] Bonaterra GA, Zügel S, Thogersen J, et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury[J]. J Am Heart Assoc, 2012, 1(6):e002550.
[17] Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE)trial[J]. Circulation, 2014, 130(21):1847-1858.
[18] Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48[J]. Circulation, 2019, 139(6):760-771.
[19] Hu YF, Chen YJ, Lin YJ, et al. Inflammation and the pathogenesis of atrial fibrillation[J]. Nat Rev Cardiol, 2015, 12(4):230-243.
[20] Rudolph V, Andrié RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation[J]. Nat Med, 2010, 16(4):470-474.
[21] Wang PY, Cheng M, Wang PX, et al. SNP rs2243828 in MPO associated with myeloperoxidase level and atrial fibrillation risk in Chinese Han population[J]. J Cell Mol Med, 2020, 24(17):10263-10266.
[22] Tan Q, Zhang SY, Zou XY, et al. Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients[J]. Anatol J Cardiol, 2017, 18(2):103-107.
[23] Zhen- Han L, Rui S, Dan C, et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: a meta-analysis[J]. Sci Rep, 2017, 7(1):10091.
[24] Darghosian L, Free M, Li J, et al. Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation[J]. Am J Cardiol, 2015, 115(2):196-201.
[25] Ozaydin M, Erdogˇan D, Tayyar S, et al. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study[J]. Anadolu Kardiyol Derg, 2011, 11(4):305-309.
[26] Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement[J]. J Am Coll Cardiol, 2013, 62(16):1457-1465.
[27] Liu C, Wang JH, Yiu DF, et al. The efficacy of glucocorticoids for the prevention of atrial fibrillation, or length of intensive care unite or hospital stay after cardiac surgery: a meta-analysis[J]. Cardiovasc Ther, 2014, 32(3):89-96.
[28] Stavrakis S, Humphrey MB, Scherlag BJ, et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation[J]. J Am Coll Cardiol, 2015, 65(9):867-875.
[29] Stavrakis S, Humphrey MB, Scherlag BJ, et al. Low-level vagus nerve stimulation suppresses post-operative atrial fibrillation and inflammation: a randomized study[J]. JACC Clin Electrophysiol, 2017, 3(9):929-938.

备注/Memo

备注/Memo:
通信作者:宋浩明,E-mail:songhao-ming@163.com
更新日期/Last Update: 2021-12-01